2.10
0.48%
+0.01
After Hours:
2.58
0.48
+22.86%
PharmaCyte Biotech Inc stock is currently priced at $2.10, with a 24-hour trading volume of 3,176.
It has seen a +0.48% increased in the last 24 hours and a -0.94% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $2.09 pivot point. If it approaches the $2.15 resistance level, significant changes may occur.
Previous Close:
$2.09
Open:
$2.06
24h Volume:
3,176
Market Cap:
$17.75M
Revenue:
-
Net Income/Loss:
$-1.14M
P/E Ratio:
-5.00
EPS:
-0.42
Net Cash Flow:
$-2.11M
1W Performance:
-2.55%
1M Performance:
-0.94%
6M Performance:
+2.94%
1Y Performance:
-32.04%
PharmaCyte Biotech Inc Stock (PMCB) Company Profile
Name
PharmaCyte Biotech Inc
Sector
Industry
Phone
917 595 2850
Address
3960 Howard Hughes Parkway, Suite 500, Las Vegas
PharmaCyte Biotech Inc Stock (PMCB) Latest News
Ascites Treatment Market Emerging Trends | Sequana Medical, BioVie, PharmaCyte Biotech - Motions Online
Motions Online
PharmaCyte Biotech (NASDAQ:PMCB) Is In A Strong Position To Grow Its Business - Simply Wall St
Simply Wall St
Femasys announces upfront investment of $6.85M by PharmaCyte - TipRanks.com - TipRanks
TipRanks
PharmaCyte Biotech Announces Final Results of Tender Offer - Yahoo Finance
Yahoo Finance
PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share - Yahoo Finance
Yahoo Finance
PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan - Business Wire
Business Wire
PharmaCyte Biotech Inc Stock (PMCB) Financials Data
PharmaCyte Biotech Inc (PMCB) Net Income 2024
PMCB net income (TTM) was -$1.14 million for the quarter ending January 31, 2024, a +79.70% increase year-over-year.
PharmaCyte Biotech Inc (PMCB) Cash Flow 2024
PMCB recorded a free cash flow (TTM) of -$2.11 million for the quarter ending January 31, 2024, a +55.15% increase year-over-year.
PharmaCyte Biotech Inc (PMCB) Earnings per Share 2024
PMCB earnings per share (TTM) was -$1.20 for the quarter ending January 31, 2024, a -361.54% decline year-over-year.
About PharmaCyte Biotech Inc
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
Cap:
|
Volume (24h):